Kathleen D. Eisenach

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Efficacy and Safety of Higher Doses of Levofloxacin for Multidrug-resistant Tuberculosis: A Randomized, Placebo-controlled Phase II Clinical Trial”.

Efficacy and Safety of Higher Doses of Levofloxacin for Multidrug-resistant Tuberculosis: A Randomized, Placebo-controlled Phase II Clinical Trial

American Journal of Respiratory and Critical Care Medicine(2025)10.1164/rccm.202407-1354oc

N/A

0.377DataRank · unranked

9 citations

Charles A. Peloquin, Timothy R. Sterling, Pawandeep Kaur, Andreas H. Diacon, Eduardo Gotuzzo +11 more

Drug susceptibility patterns of Mycobacterium tuberculosis from adults with multidrug-resistant tuberculosis and implications for a household contact preventive therapy trial

BMC Infectious Diseases(2021)10.1186/s12879-021-05884-4

N/A

0.373DataRank · unranked

11 citations

Anne‐Marie Demers, Soyeon Kim, Sara McCallum, Kathleen D. Eisenach, Michael D. Hughes +14 more

Study protocol for a duration-randomized clinical trial to determine the optimal length of treatment for multidrug-resistant tuberculosis with a 5-drug regimen: The DRAMATIC trial

Contemporary Clinical Trials(2025)10.1016/j.cct.2025.107875

N/A

0.104DataRank · unranked

1 citations

Lelia H. Chaisson, Zana Wangari Kiragu, Praewpannarai Buddadhumaruk, Ariana Austin, Yilan Gao +16 more

Quantification of multidrug-resistant M. tuberculosis bacilli in sputum during the first 8 weeks of treatment

The International Journal of Tuberculosis and Lung Disease(2022)10.5588/ijtld.21.0741

N/A

0DataRank · unranked

2 citations

Kathleen D. Eisenach, Moses Joloba, Willy Ssengooba, Carolyn Namaganda, Mary Nsereko +4 more

Future-proofing tuberculosis therapy: framework for concurrent drug and resistance testing development

The Lancet Infectious Diseases(2025)10.1016/s1473-3099(25)00547-x

N/A

0DataRank · unranked

1 citations

Seda Yerlikaya, Susan E. Dorman, Kathleen D. Eisenach, Maha R. Farhat, Nazir Ismail +10 more